Table 2.
Outcome characteristics during follow-up for switched to generic or brand-name users
| Outcomes Follow-up time characteristics |
Losartan [n = 15,783] | Valsartan [n = 16,907] | Candesartan [n = 26,178] | |||
|---|---|---|---|---|---|---|
| Switched to generics [n = 14,673] | Brand-name [n = 1110] | Switched to generics [n = 3353] | Brand-name [n = 13,554] | Switched to generics [n = 13,648] | Brand-name [n = 12,530] | |
| ER consultation (%) | 33.2† | 27.7 | 32.8‡ | 27.8 | 26.8 | 25.9 |
| Follow-up time prior to ER consultation or censoring | 312 (260)‡ | 207 (329) | 256 (275)† | 296 (270) | 199 (305)† | 212 (300) |
| Hospitalization (%) | 14.4 | 13.2 | 15.6‡ | 11.0 | 11.4 | 11.1 |
| Follow-up time prior to hospitalization or censoring | 365 (179)‡ | 334 (321) | 365 (239) | 365 (208) | 266 (275)* | 264 (254) |
| Death (%) | 0.6 | 0.9 | 0.5 | 0.6 | 0.3* | 0.4 |
| Follow-up time prior to death or censoring | 365 (125)‡ | 365 (317) | 365 (195) | 365 (175) | 278 (271) | 280 (234) |
| Incomplete 365-day follow-up time prior to censoring or any outcome (%) | 35.6‡ | 49.4 | 43.0 | 43.3 | 63.5 | 64.3 |
| Drug adjustments: ≥ 10 nonproprietary name drugs after cohort entry (%) | 44.6‡ | 37.3 | 44.6‡ | 39.0 | 43.5‡ | 39.5 |
Data are expressed as proportions or median (IQR)
Statistical significance of the difference between switched to generic (exposed) versus brand-name users assessed using the Chi square test or Wilcoxon rank-sum test
ER emergency room, IQR interquartile range
*p < 0.05, **p < 0.01, †p < 0.001, ‡p < 0.0001